PE20171320A1 - Analogos de calcitonina para tratar enfermedades y trastornos - Google Patents
Analogos de calcitonina para tratar enfermedades y trastornosInfo
- Publication number
- PE20171320A1 PE20171320A1 PE2017001166A PE2017001166A PE20171320A1 PE 20171320 A1 PE20171320 A1 PE 20171320A1 PE 2017001166 A PE2017001166 A PE 2017001166A PE 2017001166 A PE2017001166 A PE 2017001166A PE 20171320 A1 PE20171320 A1 PE 20171320A1
- Authority
- PE
- Peru
- Prior art keywords
- disorders
- treat diseases
- seq
- calcitonin analogs
- calcitonin
- Prior art date
Links
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical class N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title abstract 2
- 208000037765 diseases and disorders Diseases 0.000 title 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a un analogo de calcitonina que comprende peptidos con una secuencia de aminoacidos tales como SEC ID NO: 1, SEC ID NO:2, SEC ID NO: 3, SEC ID NO: 4, entre otros. Tambien se refiere a un metodo de tratamiento. Dicho analogo es util en la disminucion de los trigliceridos o grasa acumulados en el higado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1500263.7A GB201500263D0 (en) | 2015-01-08 | 2015-01-08 | Calcitonin analogues for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171320A1 true PE20171320A1 (es) | 2017-09-07 |
Family
ID=52597359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001166A PE20171320A1 (es) | 2015-01-08 | 2016-01-07 | Analogos de calcitonina para tratar enfermedades y trastornos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10350272B2 (es) |
| EP (1) | EP3247383A1 (es) |
| JP (1) | JP2018502854A (es) |
| KR (1) | KR20170120576A (es) |
| CN (1) | CN107206056A (es) |
| AU (1) | AU2016205994A1 (es) |
| BR (1) | BR112017014552A2 (es) |
| CA (1) | CA2969293A1 (es) |
| CL (1) | CL2017001773A1 (es) |
| CO (1) | CO2017007007A2 (es) |
| EA (1) | EA201791154A1 (es) |
| GB (1) | GB201500263D0 (es) |
| IL (1) | IL253026A0 (es) |
| MX (1) | MX2017008755A (es) |
| PE (1) | PE20171320A1 (es) |
| PH (1) | PH12017500988A1 (es) |
| WO (1) | WO2016110525A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201704429D0 (en) * | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201707955D0 (en) * | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| GB201813677D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| TWI901926B (zh) | 2020-12-18 | 2025-10-21 | 美商美國禮來大藥廠 | 雙重澱粉素及降鈣素受體促效劑及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO2000033866A1 (en) | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Pharmaceutical compositions containing insulin |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| JP2006521366A (ja) | 2003-03-28 | 2006-09-21 | シグモイド・バイオテクノロジーズ・リミテッド | シームレスマイクロカプセルを含む固形経口剤形 |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| JP4716987B2 (ja) | 2003-07-23 | 2011-07-06 | ノバルティス アーゲー | 骨関節症におけるカルシトニンの使用 |
| WO2005094785A2 (en) | 2003-09-17 | 2005-10-13 | Chiasma, Ltd. | Compositions capable of facilitating penetration across a biological barrier |
| WO2006008270A1 (de) | 2004-07-22 | 2006-01-26 | Thiomatrix Forschungs- Und Beratungs Gmbh | Verwendung von thiolgruppen-hältigen verbindungen als efflux-pumpen-hemmer |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| EP1907561B1 (en) | 2005-06-24 | 2013-08-28 | Unigene Laboratories, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| AU2006288703B2 (en) | 2005-09-06 | 2011-09-22 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| PL1834635T3 (pl) | 2006-03-13 | 2012-01-31 | Advancell Advanced In Vitro Cell Tech S A | Stabilne układy nanokapsułek do podawania cząsteczek aktywnych |
| WO2007117706A2 (en) | 2006-04-07 | 2007-10-18 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| CN102292346B (zh) * | 2009-01-22 | 2015-12-02 | 关键生物科学有限公司 | 肥胖的治疗 |
| MX351092B (es) | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
| KR20160075794A (ko) * | 2013-11-14 | 2016-06-29 | 키바이오사이언스 아게 | 질환 및 질병 치료용 칼시토닌 모방체 |
-
2015
- 2015-01-08 GB GBGB1500263.7A patent/GB201500263D0/en not_active Ceased
-
2016
- 2016-01-07 JP JP2017535736A patent/JP2018502854A/ja active Pending
- 2016-01-07 EA EA201791154A patent/EA201791154A1/ru unknown
- 2016-01-07 WO PCT/EP2016/050186 patent/WO2016110525A1/en not_active Ceased
- 2016-01-07 KR KR1020177021071A patent/KR20170120576A/ko not_active Withdrawn
- 2016-01-07 EP EP16700080.1A patent/EP3247383A1/en not_active Withdrawn
- 2016-01-07 AU AU2016205994A patent/AU2016205994A1/en not_active Abandoned
- 2016-01-07 CA CA2969293A patent/CA2969293A1/en not_active Abandoned
- 2016-01-07 CN CN201680005191.8A patent/CN107206056A/zh active Pending
- 2016-01-07 BR BR112017014552A patent/BR112017014552A2/pt not_active Application Discontinuation
- 2016-01-07 US US15/542,191 patent/US10350272B2/en not_active Expired - Fee Related
- 2016-01-07 PE PE2017001166A patent/PE20171320A1/es unknown
- 2016-01-07 MX MX2017008755A patent/MX2017008755A/es unknown
-
2017
- 2017-05-29 PH PH12017500988A patent/PH12017500988A1/en unknown
- 2017-06-19 IL IL253026A patent/IL253026A0/en unknown
- 2017-07-04 CL CL2017001773A patent/CL2017001773A1/es unknown
- 2017-07-12 CO CONC2017/0007007A patent/CO2017007007A2/es unknown
-
2019
- 2019-07-15 US US16/511,815 patent/US20190328843A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017500988A1 (en) | 2017-12-18 |
| CN107206056A (zh) | 2017-09-26 |
| AU2016205994A1 (en) | 2017-06-15 |
| EA201791154A1 (ru) | 2017-09-29 |
| US10350272B2 (en) | 2019-07-16 |
| JP2018502854A (ja) | 2018-02-01 |
| CA2969293A1 (en) | 2016-07-14 |
| US20180264085A1 (en) | 2018-09-20 |
| GB201500263D0 (en) | 2015-02-25 |
| CL2017001773A1 (es) | 2018-03-09 |
| BR112017014552A2 (pt) | 2018-05-15 |
| US20190328843A1 (en) | 2019-10-31 |
| WO2016110525A1 (en) | 2016-07-14 |
| KR20170120576A (ko) | 2017-10-31 |
| IL253026A0 (en) | 2017-08-31 |
| EP3247383A1 (en) | 2017-11-29 |
| MX2017008755A (es) | 2017-11-17 |
| CO2017007007A2 (es) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| CL2017000864A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| PE20170771A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
| SV2018005714A (es) | Composiciones y metodos para disminuir la expresion de tau | |
| PH12019501339A1 (en) | Amino acid compositions and methods for the treatment of muscle diseases and disorders | |
| PE20180128A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| UY36550A (es) | Oligómeros antisentido de tau y sus usos | |
| ECSP17056415A (es) | Anticuerpos contra tau y sus usos | |
| MX2017005030A (es) | Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio. | |
| CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
| MX388562B (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
| MX2017006113A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
| MX2022005370A (es) | Analogos de compstatina de accion prolongada para usarse en el tratamiento de trastornos oculares. | |
| CO2017007007A2 (es) | Análogos de calcitonina | |
| MX2017011879A (es) | Inhibidores de pcsk9 para el tratamiento de trastornos del metabolismo de lipoproteínas". | |
| CO2019006443A2 (es) | Peptido para tratar degeneracion macular relacionada con la edad | |
| PE20160847A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| PE20160877A1 (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion | |
| AR107460A1 (es) | Gabapentina oftálmica para el tratamiento de las úlceras corneales | |
| PE20160848A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| NI201700026A (es) | Compuestos dipeptidil cetoamídicos y su uso para el tratamiento y/o la prevención de la acumulación de grasa. | |
| MX2021008998A (es) | Celulas progenitoras adultas multipotentes para usarse en el tratamiento de la hemorragia intracerebral. | |
| ES2586805T3 (es) | Análogos de péptidos para tratar enfermedades y trastornos | |
| MX380683B (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina. | |
| MX2016017321A (es) | Combinacicones y metodos para el tratamiento de dolor neuropatico. |